Fig. 1: Trial profile. | Nature Communications

Fig. 1: Trial profile.

From: Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial

Fig. 1

* One patient was found with HER2 IHC 1+ after receiving study treatment and was excluded from efficacy analysis due to not meeting the inclusion criteria. † Five patients with brain metastasis at baseline and only intracranial progression during the study period received local stereotactic radiosurgery and resumed study treatment until the second progression at the discretion of the patients and treating physicians.

Back to article page